V ascular endothelial growth factor receptor 2 (VEGFR2) is the master regulator controlling both physiological and pathological angiogenesis. [1] [2] [3] [4] [5] [6] Vascular endothelial growth factor A (VEGF-A), secreted in response to a variety of different proangiogenic stimuli, binds to and induces the autophosphorylation of dimerized VEGFR2. 1, 5, 7 Downstream VEGFR2 signaling promotes angiogenic responses including endothelial cell proliferation, migration, and network formation.
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March 18, 2016 membrane-localizing epsin NH 2 -terminal homology domain and carboxyl-terminal clathrin-and antennapedia 2-binding motifs. 9, 16, 17, 19, 23, 25, 26 Mammals express 3 epsins as follows: epsins 1 and 2, which are ubiquitously expressed and redundant in function, and epsin 3, which is expressed primarily in the stomach and epidermis. 9, 10, 14, 19, [27] [28] [29] [30] Germ line epsins 1 and 2 double knockout (DKO) mice exhibit severe vascular defects resulting in embryonic lethality. 10, 27 In contrast, we previously discovered that inducible deletion of epsins 1 and 2 in endothelial cells in adult double knockout mice (EC-iDKO) has minimal effects on quiescent vascular beds but significantly alters tumor angiogenesis resulting in hyperplastic, dilated, and dysfunctional tumor vascular networks resulting in retarded tumor growth. 9, 10 We previously reported that in endothelial cells, epsins 1 and 2 preferentially bind ubiquitinated VEGFR2 to mediate its lysosomal degradation and subsequent signaling attenuation. 9, 10 Loss of epsins impairs VEGFR2 downregulation, resulting in elevated VEGFR2 level and heightened VEGF signaling. 9 Interestingly, epsin loss does not affect other angiogenic receptors and their downstream signaling, including platelet-derived growth factor receptor, fibroblast growth factor receptor, epidermal growth factor receptor, and transforming growth factor beta receptor, 9 suggesting that epsins are unique adaptor proteins for VEGFR2 endocytosis and degradation in endothelial cells. In further support, our recent study showed that genetic reduction of VEGFR2 in endothelial cells decreases elevated VEGF signaling and rescues aberrant angiogenesis caused by epsins 1 and 2 deficiencies. 10 Intriguingly, epsins 1, 2, and 3 have been implicated in the generation of membrane curvature that is critical for clathrin-mediated endocytosis. 31 Deficiency of all 3 epsins impairs endocytosis in general by stalling the actin-dependent invagination of endocytic clathrin-coated pits. 31 However, our previous study clearly demonstrated that prototypical clathrin-mediated endocytosis of transferin receptor and epidermal growth factor receptor still occurs in both global knockout and endothelial-specific knockout of epsins 1 and 2 mice. 9, 27 Thus, deficiency of epsins 1 and 2 in either primary endothelial cells or mouse embryonic fibroblasts does not impair housekeeping clathrin-mediated endocytosis.
Despite a specific role for epsins 1 and 2 in regulating VEGFR2 endocytosis and degradation, how the binding specificity between VEGFR2 and epsins is achieved was poorly understood. Although we previously determined that the epsin-VEGFR2 interaction is dependent on the epsin UIM and that deletion of UIM completely abolishes the binding of epsin to VEGFR2, 9 ,10 the molecular determinants that govern this specific interaction remain unknown. A detailed understanding of the molecular mechanisms driving this unique specificity will provide potential new therapeutic strategies to spatially and temporally promote favorable physiological angiogenesis, and also restrain undesirable pathological angiogenesis. Herein, we uncovered novel-binding mechanisms that drive the specific interaction between epsin and VEGFR2. Using structural modeling, we have identified unique residues in the epsin UIM and VEGFR2 that reciprocally determine the specific interaction between epsin and VEGFR2. Guided by these discoveries, we designed an epsin inhibitory UIM peptide that effectively blocked the interaction between epsin and VEGFR2, thereby promoting VEGFR2 signaling and angiogenesis in vitro. Consistently, administration of the inhibitory peptide into wildtype (WT) mice potentiated postnatal retina angiogenesis and VEGF-mediated angiogenesis in subcutaneous Matrigel plugs. Similar proangiogenic effects were also observed after dermal wound healing, where UIM peptide administration enhanced physiological angiogenesis and wound healing relative to control peptide. These responses were not observed with a mutant UIM peptide containing substitutions at the critical VEGFR2-binding residues. Collectively, our studies have revealed previously unappreciated molecular mechanisms underlying the specific epsin-VEGFR2 interaction, and identified unique molecular determinants of epsin-VEGFR2 complex assembly that are critical to regulate physiological angiogenic processes.
Methods
Complete Methods are available in the Online Data Supplement.
Results

Epsin UIM Mediates VEGFR2 Signaling and Interacts With the VEGFR2 Kinase Domain
We previously showed that epsins facilitate the internalization and degradation of activated VEGFR2, but not other angiogenic modulators, via interactions between epsin UIM and VEGFR2 kinase domain (KD). 9 We created an inducible endothelial cell-specific epsin-deficient mouse line by crossing Epsin1 fl/fl ; Epsin2 −/− mice (EC-iDKO; Online Figure IA ) with iCDH5 Cre deleter mice that express Cre recombinase specifically in endothelial cells after tamoxifen administration (Online Figure  IB) . 9 Using primary mouse endothelial cells (MECs) isolated from WT or EC-iDKO mice, we demonstrated that loss of epsin promoted VEGF-dependent VEGFR2 phosphorylation (Online Figure IIA) , consistent with impaired internalization and degradation of activated VEGFR2. Moreover, expression of WT epsin 1 (hemagglutinin-Epsin 1), but not UIM-deficient epsin 1 (hemagglutinin-Epsin 1-ΔUIM), in DKO MECs restored VEGFR2 signaling (Online Figure IIA) , further indicating the importance of the epsin UIM to VEGF-dependent VEGFR2 internalization. The UIM interacts with ubiquitin moieties with low affinity and minimal specificity 12, 16, 23, 25 ; however, we have revealed that it regulates VEGFR2 specifically. Thus, how the epsin UIM achieves this specific interaction VEGFR2 is intriguing. To explore the molecular mechanism underlying this binding specificity, we used structural modeling with PEP-FOLD and ClusPro softwares. 32 We uncovered a novel putative epsin UIM binding cleft within the VEGFR2 KD ( Figure 1A and 1B :VEGFR2 R1080 ( Figure 1B ; Online Figure IIC ; Online Table I ). Indeed, E184 and E185 within the predicted epsin UIM-VEGFR2 binding domain are highly conserved between mouse, zebrafish, Xenopus, and human epsins 1 and 2 ( Figure 1C ). Our findings suggest that, in addition to the traditional binding between the epsin UIM and the ubiquitin moiety on VEGFR2, epsins may also selectively interact with VEGFR2 via specific protein-protein interactions.
To investigate the molecular binding mechanism described above, we substituted specific residues within the putative binding clefts in VEGFR2 KD and epsin UIM and evaluated their effects on the VEGFR2-epsin interaction. We used site-directed mutagenesis to create expression constructs with mutated versions of VEGFR2, and expressed these wild-VEGFR2 in human umbilical vein endothelial cells (HUVEC) as indicated ( Figure 1D ). Cells were subsequently stimulated with VEGF to induce VEGFR2 activation and ubiquitination, and processed for immunoprecipitation using epsin 1-specific antibody as previously described ( Figure 1D) . 9, 33 We found that WT-VEGFR2 coimmunoprecipitated with epsin1; however, all of the VEGFR2 mutants impeded binding to epsin1 ( Figure 1D ). Likewise, substitutions at the corresponding residues in hemagglutinin-tagged full-length epsin1, E183A, E184A, and E185A also abolished VEGFR2 immunoprecipitation by epsin 1 ( Figure 1E ). Notably, impaired VEGFR2 binding by hemagglutinin-epsin 1 E183,184,185A was comparable to UIM-deficient epsin 1. However, the mutation of other Figure 1 . The Epsin ubiquitin interacting motif (UIM) mediates vascular endothelial growth factor receptor 2 (VEGFR2) signaling and interacts with the VEGFR2 kinase domain (KD). A, Ribbon representation and (B) stick representation of epsin UIM (green) docked into the putative hairpin-shaped binding pocket of VEGFR2 KD (blue). VEGFR2 KD crystal structure (3U6J) was obtained from the Protein Data Bank. Ribbon diagram for epsin UIM was predicted using PEP-FOLD. ClusPro and PyMol software were used for the docking; highest scoring model with good topologies is shown. C, Alignment of epsin UIM sequences from mouse, rat, and human epsins 1 and 2. Note: E183 (corresponding to E3 in UIM peptide), E184 (corresponding to E4 in UIM peptide), and E185 (corresponding to E5 in UIM peptide) are highly conserved. Figure 1B ) did not disrupt VEGFR2 immunoprecipitation (Online Figure IID) . These findings emphasize the critical importance of the epsin UIM for binding to this novel VEGFR2 interface, and identify key residues that achieve specificity of this interaction, in particular H891 of VEGFR2 and E183, E184, and E185 of the epsin UIM.
c-Cbl-Dependent Ubiquitination of Epsin Promotes the Interaction With VEGFR2
VEGF stimulation reportedly induces VEGFR2 ubiquitination via the recruitment of casitas B-lineage Lymphoma E3 ubiquitin-protein ligase (c-Cbl). 3 Interestingly, epsins are also reportedly ubiquitinated under some conditions, 22, 34 including VEGF stimulation (Figure 2A ). To determine whether epsin ubiquitination is mediated by c-Cbl, we used RNAi to deplete c-Cbl in HUVECs before serum starvation and VEGF stimulation. We found that VEGF-dependent epsin 1 ubiquitination was abolished in c-Cbl depleted HUVECs compared with control siRNA-treated cells (Figure 2A ). Furthermore, we observed that epsin-VEGFR2 interaction is increased by c-Cblmediated ubiquitination of epsin ( Figure 2A ). Conversely, epsin-VEGFR2 interaction is completely inhibited by c-Cbl knockdown ( Figure 2A ). Given that c-Cbl-dependent ubiquitination of epsin is increased in response to VEGF stimulation (Figure 2A ), we next tested whether ubiquitination of epsin is facilitated by its interaction with VEGFR2. We cotransfected VEGFR2 with full-length hemagglutinin-Epsin 1, hemagglutinin-Epsin 1-ΔUIM, or hemagglutinin-Epsin 1 E183,184,185A into HUVEC cells and evaluated epsin ubiquitination by immunoprecipitation/Western blot. We found that both hemagglutinin-Epsin 1-ΔUIM and hemagglutinin-Epsin 1 E183,184,185A
, which do not interact with VEGFR2 ( Figure 1E ), show reduced epsin ubiquitination compared with hemagglutinin-Epsin 1 ( Figure 2B ). Collectively, our data suggest that VEGF enhances c-Cbl-mediated epsin ubiquitination, which in turn reinforces the interaction between epsin and VEGFR2.
Interestingly, our structural modeling also identified a novel interface in the VEGFR2 KD that is predicted to interact with an ubiquitin moiety, such as the ubiquitin on epsin ( Figure 3A) . Among the residues within VEGFR2 that could potentially interact with ubiquitin, we found that VEGFR2 H891 and VEGFR2 S1021 form 2 critical interacting surfaces with ubiquitin, VEGFR2
H891
:ubiquitin R72,74 and VEGFR2
S1021
:ubiquitin
R42
( Figure 3A ). More importantly, we found that both VEGFR2
H891
and VEGFR2 S1021 interfaces are critical for its interaction with epsin (Online Figure ID ; Figure 3B ). We also found that purified VEGFR2 specifically immunoprecipitated both mono-and poly-ubiquitin chains, further supporting this novel ubiquitininteracting interface ( Figure 3C ). In addition, pull-down by di-ubiquitin was significantly impaired by disruption of the putative ubiquitin-binding motif in VEGFR2
H981A or VEGFR2 S1021A ( Figure 3D ). To determine whether this interface contributes to the interaction with ubiquitinated epsin, we conjugated hemagglutinin-tagged full-length epsin 1-fusion proteins to WT or mutant ubiquitin moieties ( Figure 3C ). 35, 36 Biochemical and structural studies have revealed the importance of isoleucine 44 within ubiquitin for binding to ubiquitin interaction domains 16 ; thus, the ubiquitin I44A mutation serves as a positive control that disrupts its interaction with ubiquitin-interacting proteins. [37] [38] [39] We evaluated the contribution of the residues R42, R72, and R74 in ubiquitin that are predicted to interact with VEGFR2 by coexpressing VEGFR2 with hemagglutinin-Epsin 1-ubiquitin Figure 3E ), followed by VEGF stimulation. We found that VEGFR2 coimmunoprecipitated hemagglutinin-Epsin 1-ubiquitin WT , but not hemagglutinin-Epsin 1-ubiquitin I44A ( Figure 3F ), suggesting that VEGFR2 interacts with the ubiquitin moiety conjugated to epsin. Importantly, both hemagglutinin-Epsin 1-ubiquitin R72A, R74A and hemagglutinin-Epsin 1-ubiquitin R42A also displayed significantly impaired VEGFR2 coimmunoprecipitation ( Figure 3F ). These findings suggest that c-Cbl-dependent ubiquitination of epsin creates a binding site for the novel ubiquitin-interaction interface of VEGFR2, and thus may contribute to the specificity of epsin for VEGFR2. We next determined the importance of our newly identified ubiquitin-and epsin UIM-interacting interfaces in VEGFR2 . Cells were serum-starved overnight and stimulated with 50 ng/mL VEGF for 2 minutes. C, Western blot analysis of mono-or poly-ubiquitin pulldown by wild-type VEGFR2 overexpressed in HEK 293T cells. D, Western blot analysis of VEGFR2 pulldown by di-ubiquitin in HEK 293T cells overexpressing wild-type VEGFR2, VEGFR2 H891A , or VEGFR2 S1021A . E, Putative interacting residues of VEGFR2 and ubiquitin with their respective hydrogen bond distances, and schematic representation of epsin 1 conjugated to wild-type ubiquitin or ubiquitin with I44A, R42A or R72A, and R74A substitutions. F, Western blot analysis of epsin 1 coimmunoprecipitation with VEGFR2 in HEK 293T cells overexpressing wild-type VEGFR2 and hemagglutinin (HA)-Epsin1 conjugated to wild-type ubiquitin (HA-Epsin 1-Ub) or ubiquitin with I44A, R42A, R72A, or R74A point substitutions. Cells were serum-starved overnight and stimulated with 50 ng/mL VEGF for 2 minutes. All representative Western blots were selected from n=3. Error bars indicate the mean±SEM; *P<0.05. H891A VEGFR2 S1021A mutants that disrupt critical interactions with residues in epsin and ubiquitin. Expression of either VEGFR2
H891A or VEGFR2 S1021A significantly enhanced VEGF-induced phosphorylation of VEGFR2 (p-VEGFR2) and downstream signaling components, including phosphorylation of protein kinase B (p-AKT) and extracellular signal-regulated kinase (p-ERK) relative to VEGFR2 WT ( Figure 4A ). Furthermore, compared with VEGFR2 WT , both VEGFR2
H891A and VEGFR2 S1021A mutants exhibited impaired VEGF-induced endocytosis and decreased colocalization with EEA1, an endosomal marker ( Figure 4B ). The reduced endocytosis of VEGFR2 H891A and VEGFR2 S1021A mutants was further examined by surface biotinylation. After VEGF stimulation, we observed more VEGFR2 H891A and VEGFR2
S1021A
at the cell surface compared with VEGFR2 WT ( Figure 4C ). Collectively, these findings suggest that the specificity with which epsins preferentially bind and modulate VEGFR2 internalization is guided by multiple mechanisms, including epsin UIM binding to ubiquitinated VEGFR2, 9,10 ubiquitin-independent VEGFR2 binding to epsin UIM (Figure 1 Our discovery that E183A, E184A and E185A substitutions within the epsin UIM significantly abolished its VEGFdependent interaction with VEGFR2 ( Figure 1E ) suggests that these residues contribute to the specificity and affinity of the interaction. To further establish the importance of epsin UIM E183, E184, and E185 and to investigate the feasibility of targeted epsin inhibition, we created a synthetic UIM-containing peptide designed to competitively inhibit UIM-dependent epsin binding to VEGFR2. Importantly, we synthesized this UIM peptide with a plasma membrane permeable peptide, antennapedia (also known as penetratin), to ensure intracellular delivery. 40 We also created a mutant UIM peptide (UIM E3,4,5A ) by incorporating 3 glutamic acid-to-alanine substitutions (E3A, E4A, and E5A) within the UIM peptide sequence that correspond to E183, E184, and E185 of the epsin UIM. On the basis of our findings, the mutant UIM peptide should not compete with epsin binding to VEGFR2. We treated human embryonic kidney (HEK) 293T cells transfected with VEGFR2 and hemagglutinin-Epsin 1 with either UIM or UIM E3,4,5A peptide for 16 hours before VEGF stimulation, then processed the lysates for immunoprecipitation using hemagglutinin-specific antibody ( Figure 5A ). The UIM peptide, but not the mutant UIM E3,4,5A peptide, competitively inhibited hemagglutininepsin 1 binding to VEGFR2 ( Figure 5A ). Consistent with impaired epsin binding to VEGFR2, the UIM peptide enhanced VEGFR2 protein levels and downstream signaling in WT MECs pretreated for 16 hours with peptide before serum starvation and VEGF stimulation ( Figure 5B ). Importantly, the results obtained using the novel UIM peptide closely mimicked the effects of epsin depletion on VEGFR2 protein levels and downstream signaling. 9, 10 These findings provide further support for the critical importance of the molecular determinants we identified herein, and suggest the therapeutic potential of this innovative UIM peptide to effectively alter angiogenesis.
Next, we wanted to determine whether the UIM peptide can sufficiently inhibit epsin function to alter VEGFdependent angiogenesis. We examined the effects of UIM peptide treatment on MEC proliferation, migration, and network formation using EdU (5-ethynyl-2′-deoxyuridine) incorporation, 10 ,41 scratch wound, 42 and Matrigel network formation assays, 42 respectively. In all these approaches, WT MECs were pretreated with UIM WT or mutant peptides for 16 hours followed by VEGF stimulation. We found that treatment with the UIM peptide significantly enhanced the in vitro angiogenic characteristics of MECs relative to the control peptide, including increased proliferation ( Figure 5C 
Physiological Angiogenesis Is Increased by Administration of UIM, but Not UIM E3,4,5A Peptides
The development of the innovative UIM peptide provides a unique opportunity to examine the therapeutic potential of exogenously inhibiting epsin function in vivo. Given that retinal angiogenesis occurs primarily during postnatal development, 43, 44 we examined the effects of control, UIM, or UIM E3,4,5A peptide administration on early postnatal angiogenesis and vascular network maturation in WT mice pups. Peptides were administered via intraperitoneal injection at postnatal days 2, 3, 4, and 5, and retinas were harvested at postnatal day 6 for whole-mount immunofluorescence staining using the endothelial cell marker, isolectin B4. Consistent with our in vitro angiogenesis experiments, the UIM peptide enhanced angiogenesis, characterized by increased vessel diameter in the postnatal day 6 retina (Figure 6A and 6B; Online Figure III ), relative to control or UIM E3,4,5A peptide. These findings further establish epsins, specifically the epsin UIM, as a critical determinant of physiological angiogenesis. To confirm that the epsins are the sole target of the UIM, UIM peptides were administered to EC-iDKO mice pups in which epsins are depleted specifically in endothelial cells. Abnormal and elevated angiogenesis in retina were observed in control peptide-treated EC-iDKO pups, providing further support that epsin is required for proper angiogenesis ( Figure 6C and  6D) . Administration of the UIM peptide did not exacerbate the retinal angiogenesis abnormality observed in EC-iDKO pups Figure 6C and 6D), suggesting that the UIM peptide is specific for epsin and does not cause off-target effects on other proangiogenic regulators.
To test whether the UIM inhibitory potential is VEGFdependent, we subcutaneously implanted Matrigel plugs containing VEGF and control, UIM, or UIM E3,4,5A peptide into WT adult mice to directly examine the effects of UIM peptide treatment on endothelial cell migration and network formation in vivo. As predicted, the UIM peptide caused significant proangiogenic effects on the Matrigel, resulting in enhanced vascularization ( Figure 6E ). Mutating the 3 glutamic acids within the UIM peptide significantly impaired Matrigel vascularization, relative to UIM peptide ( Figure 6E ), further establishing that the epsin UIM is the critical domain responsible for epsinmediated angiogenic regulation. Immunofluorescent staining of cryosections from the Matrigel plugs with CD31-specific , or VEGFR2 S1021A using a cleavable surface biotinylation and internalization assay. Cells were serum-starved overnight and stimulated with 50 ng/mL VEGF for 10 minutes. All representative Western blots and immunofluorescence images were selected from n=3. Error bars indicate the mean±SEM; *P<0.05. Scale bar in B: 10 μm.
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antibody further confirmed the enhanced vascularization and revealed increased vessel dilation in the UIM peptide-containing Matrigel plugs ( Figure 6F and 6G). In contrary, this effect was not observed if the Matrigel plugs contained control or UIM E3,4,5A peptide. Of note, UIM peptide administration to Matrigel plugs implanted in EC-iDKO mice did not cause additional vascular abnormalities compared with control peptide treatment ( Figure 6H and 6I) .
Finally, to determine whether the proangiogenic effects of our UIM peptide can provide therapeutic benefits, we examined the effects of UIM peptide administration on wound healing, a physiological process dependent in part on enhanced angiogenesis. We used a previously established 5 dermal biopsy procedure to create 4 circular wounds on the shaved back of WT mice and administered control or UIM peptide via peritoneal injection daily for 7 days while monitoring wound healing ( Figure 7A ). 5 UIM peptide administration significantly accelerated wound healing, relative to control peptide ( Figure 7A and 7B) , suggesting that the UIM peptide does effectively enhance wound-healing angiogenesis. Consistently, CD31-specific immunofluorescence staining of wounds isolated from UIM-peptide-treated WT mice at day 7 revealed significantly more vascularization of the wound area ( Figure 7C and 7D). Thus, 3 critical glutamic acid residues within the epsin UIM mediate the specificity of binding to VEGFR2 in endothelial cells, likely through interactions with H891 of VEGFR2. Furthermore, our study demonstrates the 
Discussion
Angiogenesis is essential to achieve and maintain physiological homeostasis. Disruptions in the regulatory signaling pathways such as VEGF-VEGFR2 can have devastating physiological and pathological consequences and have therefore been a major research focus. In fact, the development of anti-VEGF antibody therapy has been extremely successful in the clinical treatment of cancers with elevated VEGF secretion and hyperangiogenic phenotypes. 44, 45 Development of angiogenic promoters for clinical use in wound healing, ischemia, and other conditions in which impaired angiogenesis are common have been more restricted because of the complex regulatory events controlling VEGF-VEGFR2 signaling activation and propagation.
Although receptor internalization is a recognized mechanism of signal modification, and that there have been conflicting reports that VEGFR2 internalization is necessary for signal propagation, we have demonstrated in several publications that, at least in conditions in which epsins are deficient or inhibited, VEGFR2 is capable of signaling downstream to ERK and AKT from the cell surface. 9, 10, 46 We hypothesize that interactions between different adaptor proteins may facilitate VEGFR2 internalization and incorporation into recycling signaling endosomes thereby amplifying VEGFR2 signaling cascades. In contrary, VEGFR2 activation results in VEGFR2 ubiquitination and subsequent epsin-mediated VEGFR2 internalization and degradation. Loss of epsins may shift the fate of activated cell surface VEGFR2 from degradation to recycling, thus providing a feasible explanation for heightened VEGFR2 signaling and increased angiogenesis. More importantly, consistent with what we have reported, using matrix immobilized VEGF, multiple independently published articles Figure 7 . Ubiquitin interacting motif (UIM) peptide administration increases physiological angiogenesis in wild-type mice. A, Representative images of dermal wound healing 0, 1, 3, and 7 days after dermal biopsy of wild-type mice receiving control or UIM peptide by intraperitoneal injection. B, Quantification of wound area shown in (A) and reported as a wound-healing curve. C, Representative images of CD31-positive blood vessels in cryopreserved, sectioned, and immunfluorescently stained dermal wounds from control or UIM peptide-treated wild-type mice isolated 7 days after dermal biopsy. D, Quantification of CD31-positive vessel area relative to total vessel area of immunofluorescently stained dermal wounds from (C) using SlideBook software. All representative dermal wound and immunofluorescence images were selected from n=3 mice. Scale bars: (A) 2 mm; (C) 50 μm. Error bars indicate the mean±SEM; *P<0.05; **P<0.01. by guest on August 11, 2017 http://circres.ahajournals.org/
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have provided compelling evidence that immobilized VEGF can activate VEGFR2 and stimulate downstream signaling without VEGFR2 internalization. [47] [48] [49] Furthermore, increased cell surface VEGFR2 levels and heightened VEGF signaling as demonstrated by enhanced phosphorylation of VEGFR2, PLCγ, ERK, and AKT were observed when VEGFR2 endocytosis was blocked by loss of dynamin 2. 50 We previously reported that genetic ablation of epsins 1 and 2 in vascular endothelial cells significantly enhances angiogenesis. 9, 10 Further examination determined that epsins modulate angiogenesis by binding to and facilitating the internalization and downregulation of activated VEGFR2. Given that epsins were previously implicated as regulators of Notchmediated vasculogenesis during embryonic development, 27 we previously confirmed that epsin depletion specifically modulated VEGFR2 signaling in postnatal angiogenesis by overexpressing the active form of Notch, Notch intracellular domain, in epsin-deficient endothelial cells. Notch intracellular domain did not rescue angiogenesis suggesting that, at least in postnatal conditions, epsin modulates angiogenesis independent of Notch signaling. 9 In contrary, our study further demonstrated that genetic VEGFR2 haploinsufficiency does rescue the hyperangiogenic phenotype of EC-iDKO mice, 10 thus firmly establishing epsins as a specific regulator of VEGFR2 signaling.
Interestingly, generation of membrane curvature that is critical for clathrin-mediated endocytosis has reportedly to be assisted by epsin 1, 2, and 3. 31 Lack of all 3 epsins can impair endocytosis by stalling the actin-dependent invagination of endocytic clathrin-coated pits. 31 However, our study clearly demonstrated that lack of epsins 1 and 2 specifically blocks VEGFR2 endocytosis but not prototypical clathrin-mediated endocytosis, such as transferin receptor and epidermal growth factor receptor endocytosis in endothelial cells, suggesting that epsin 3 in these cells may compensate to support the housekeeping clathrin-mediated endocytosis. In support, we have detected expression of epsin 3 in endothelial cells including HUVECs (Online Figure VII) .
In this study, we delved into the molecular details determining the specificity between epsin and VEGFR2. In doing so, we identified 2 novel binding interfaces that function independently of the previously established interaction between epsin UIM and the ubiquitin moiety conjugated to activated VEGFR2. 9, 10 . Our findings suggest that epsin and VEGFR2 binding is guided by a complex and multifaceted binding mechanism that involves both ubiquitin-independent and ubiquitin-dependent interactions. Specifically, our complementary structural modeling and site-directed mutagenesis approaches determined that epsin UIM interacts with the VEGFR2 KD before or independent of VEGFR2 ubiquitination (Figure 1 ). VEGF-dependent activation of VEGFR2, and subsequent recruitment of c-Cbl, results in the ubiquitination of both VEGFR2 and epsin (Figure 2A ). Epsin then binds ubiquitinated VEGFR2 via the classical epsin UIM function as an UIM, whereas the novel ubiquitin interacting interface of VEGFR2 KD binds ubiquitinated epsin. Whether these interactions occur in a specific sequential order remains to be determined, but given that disrupting the ubiquitin-independent interface between epsin UIM and VEGFR2 impaired epsin ubiquitination ( Figure 2B ) and abolished VEGFR2 binding ( Figure 1E ), we speculate that this is the limiting event required for epsin and VEGFR2 to interact. Furthermore, disrupting this interface may provide a highly selective therapeutic targeting strategy.
Toward this end, we developed an innovative UIM peptide designed to competitively inhibit epsin UIM binding to VEGFR2. Foresight to include the cell-penetrating antennapedia motif significantly enhanced UIM peptide delivery and efficacy, such that UIM peptide treatment significantly promoted angiogenesis in WT, but not EC-iDKO mice (Figure  6A-6D ; Online Figure IV) . Also as further testament to peptide delivery and the importance of the critical ubiquitinindependent epsin UIM binding to VEGFR2, replacing the 3 critical glutamic acids with alanine in the UIM peptide abolished its proangiogenic effects (Figures 5 and 6 ; Online Figure  VIII) . We think that this peptide will become an essential and much needed tool for future investigations into the multivalent roles of epsin UIM in other cellular processes in which epsins have been implicated. Furthermore, we think that this study provides an important proof-of-concept for the use of similar peptide-targeting strategies to disrupt epsin function and promote angiogenesis in clinical conditions such as ischemia, surgical recovery, and secondary diabetic peripheral ulcerations where VEGF secretion or VEGFR2 expression is limited because of alternative mechanisms. [51] [52] [53] [54] For such future clinical purposes, the UIM peptide must be further refined to ensure specific endothelial cell targeting and additional experimentations need to be completed to ensure limited off-target effects. Although preliminary studies in which the UIM peptide was conjugated with fluorescein isothiocyanate (FITC-UIM) suggests that it selectively targets vascular endothelial cells (Online Figure IIIB) , an alternative future approach should include the incorporation of an endothelial-specific targeting sequence to ensure such selectivity. Novel studies on effective UIM peptide designs and their implications in clinically relevant models of altered angiogenesis are a major focus and future direction of our research.
In summary, our study identified critical molecular determinants responsible for epsin-mediated VEGFR2 downregulation and angiogenic attenuation, including 2 novel VEGFR2 interfaces predicted to engage epsin before and in addition to epsin UIM binding to ubiquitinated VEGFR2. We postulate that multiple layers of presumably weak interactions, including those between epsin UIM and the VEGFR2 KD binding cleft, between ubiquitinated epsin and the VEGFR2 KD ubiquitin-interacting interface, and between epsin UIM and ubiquitinated VEGFR2, ultimately establish a specific and stable interaction between epsin and VEGFR2 in response to VEGF stimulation (Online Figure IX) . Our data further suggest that epsins play a more critical role in VEGFR2 turnover than previously thought. Rather than simply mediating the internalization of ubiquitinated VEGFR2, our unpublished results suggest that epsins are critically involved in the ubiquitination of VEGFR2 by recruiting and interacting with c-Cbl in response to VEGF stimulation. Although the molecular determinants regulating the interaction between epsin and c-Cbl, and
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March 18, 2016 the c-Cbl-dependent ubiquitination sites within epsin have yet to be identified, our data strongly suggest that these events are critical prerequisites for epsin and VEGFR2 complex assembly and c-Cbl-dependent VEGFR2 and epsin ubiquitination. Collectively, our findings highlight the multivalent nature of epsins and the continued potential for new functional discoveries on how these unique and versatile proteins modulate specific cell functions. Importantly, these discoveries resulted in the development of an innovative and highly specific epsin inhibitory peptide that can be used in the future to investigate the epsin-dependent regulation of other cardiovascular disease processes.
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What New Information Does This Article Contribute?
• Identified novel interactions governing epsin-VEGFR2 binding.
• Designed peptide inhibitor that specifically disrupts these interactions.
• Targeting these interactions may provide an effective means to enhance angiogenesis in cases where it is inadequate.
A thorough understanding of VEGF-dependent vascular remodeling is critical for the effective design of therapies that can promote angiogenesis in cases where it is inadequate or diminish it where it is excessive. Although many advances have been made on intracellular trafficking that regulates VEGF signaling, several aspects are still poorly understood. In particular, the thorough analysis of the contribution of endocytosis to the regulation of the duration and magnitude of VEGF signaling pathways has not been fully explored and is the focus of this study. Epsin mediates VEGFR2 internalization and degradation to tightly regulate angiogenesis. However, the specific determinants of epsin-VEGFR2 interaction were unknown. Here, we have identified 2 novel binding surfaces on the VEGFR2. When mutated, these sites disrupt the binding of the epsin UIM with ubiquitinated VEGFR2, a key step in the classical epsin-dependent internalization and degradation of VEGFR2, and subsequent attenuation of angiogenesis. Furthermore, we have designed a novel UIM peptide, which competitively inhibits the epsin UIM binding to VEGFR2, consequently enhancing angiogenesis. We think that our studies on the therapeutic potential of the epsin UIM peptide in angiogenesis will pave the way for further application of this unique peptide to treat a range of cardiovascular diseases. Antibodies and reagents: Unless specified otherwise, common laboratory chemicals and reagents were from either Sigma-Aldrich or Fisher Scientific. Media and additives for cell culture were from Gibco, Mediatech or Biowest. Mouse anti-GAPDH, anti-c-Cbl, anti-Transferrin Receptor (CD71), EEA 1 and goat anti-epsin 1 antibodies were from Santa Cruz (sc-166545, sc-1651, sc-32272, sc-6145 and sc-8673). Rabbit anti-epsin 1 and 2 antibodies were previously described 1, 2 . Rabbit anti-epsin 3 antibody was from Abcam (ab 185577). Rat anti-CD31 antibody was from BD Pharmingen (550274). Rabbit anti-VEGFR2, rabbit anti-phospho-VEGFR2 (pY1175), rabbit anti-AKT, rabbit anti-phospho-Akt (pS473), mouse anti-ERK (p44/42 MAPK), and mouse anti-phospho-ERK (p-p44/42 MAPK; pT202/pY204) antibodies were from Cell Signaling Technology (2479, 2478, 9272s, 9271s, 4695s, 9106s) . Mouse anti-HA antibody was from Covance (MMS-101-P). Mouse anti-ubiquitin antibody was from Cytoskeleton (AUB01). Mouse anti-tubulin antibody (12G10) was from Developmental Studies Hybridoma Bank. Rabbit anti-epsin 1 & 2 were obtained as previously described [2] [3] [4] Biotinylated isolectin B4 was from Vector Laboratories (B-1205). Secondary antibodies and fluorescently labeled streptavidin were from Invitrogen and Jackson ImmunoResearch Laboratories. VEGF-A was from R&D systems (293-VE/CF). EdU (A10044) and Alexa Fluor 594 Azide (C10339) were from Invitrogen. Matrigel was from BD Biosciences (354230). Peptides were purchased from China Peptides. Peptide sequences are as listed: AP-Scrambled Peptide -RQIKIWFQNRRMKWKKQLSQEKAESMELALEGEL; AP-UIM Peptide -RQIKIWFQNRRMKWKKSGEEELQLQLALAMSKEE; AP-UIM E3,4,5A Peptide -RQIKIWFQNRRMKWKKSGAAALQLQLALAMSKEE.
Conditional endothelial cell-specific epsin deficient mouse generation (EC-iDKO): Epn2
-/-mice were obtained as described 5 . Conditional Epn1 fl/fl mice were obtained as described (Online-Only Figure IA) 1 . Epn1 fl/fl mice were mated with Epn2 -/-mice to generate Epn1 fl/fl ; Epn2 -/-mice. Tamoxifen-inducible endothelial cell-specific DKO mice (EC-iDKO) were obtained by crossing Epn1 fl/fl ; Epn2 -/-mice with iCDH5-ER T2 Cre deleter mice on C57BL/6J background (Online-Only Figure IB) 1, 2, 6 . To induce early postnatal deletion, pups were administered 50 µg of 4-hydroxytamoxifen by intraperitoneal injection once daily on postnatal day (P) 2, P3, P4 2, 6, 7 . All mice were bred on C57BL/6J background 1, 2 .
Structural modeling: (1) Molecular Dynamics Simulation:
The three-dimensional (3D) structures of epsin UIM was predicted by PEP-FOLD (http://bioserv.rpbs.univ-parisdiderot.fr/PEP-FOLD) 8, 9 . In this method, models were clustered by the sOPEP energy value (the coarse grained energy), and then ranked based on their cluster scores. Among the top 5 ranks, the first model of epsin UIM with best score was selected for docking experiment (Online-Only Figure IVA) . (2) Molecular Docking Procedure: Docking experiments were performed using ClusPro program 10, 11 . The 3D crystal structures of ubiquitin (PDB ID: 1UBQ), VEGFR2 kinase domain (PDB ID: 3U6J) and epsin 1 ENTH domain (PDB ID: 1H0A) were obtained from PDB Data Bank. The apo-open form of crystal structure of VEGFR2 kinase domain was obtained by removing pyrazolone, the co-crystallized VEGFR2 kinase inhibitor, from its binding site. Simulated models of epsin UIM or established ubiquitin structure were then docked into the VEGFR2 kinase domain independently to generate predicted binding models. Models with the highest scores and good topologies were selected as candidate structures for the proposed models of interaction: epsin UIM:VEGFR2 KD or ubiquitin:VEGFR2 KD. Epsin 1 ENTH was further docked into ubiquitin:VEGFR2 KD to generate the model of Epsin:Ubiquitin:VEGFR2 KD super complex.
Cell culture: HEK 293T cells (CRL-11268) and MCF-7 cells (HTB-22) were purchased from ATCC and cultured at 37 °C with 5% CO 2 in DMEM (Mediatech; 10-013-CM) supplemented with 10% fetal bovine serum (FBS; Biowest; 501520H1). Human umbilical vein endothelial cells (HUVEC) were purchased from Lonza, cultured according to the manufacturer's protocol and used between passages 2 and 5. Primary mouse endothelial cells (MEC) were isolated from mouse lungs or brains and cultured as described previously 12 . In short, for MECs isolation from the lungs, 4-6 mouse neonatal pups (7-14 days old) were used. Initially a 25-µl intramuscular injection of heparin (1,000 USP U/ml) was injected to each mouse. After 10 minutes, the mice were anesthetized, followed by exposure of the thoracic cavity. To flush blood cells from lungs, 5 ml of ice cold DMEM was then injected via the right ventricle. 1ml of collagenase Type 1(1mg/ml; Gibco Laboratories) was then quickly instilled through the trachea into the lungs, and the trachea was then tied off. The lungs (without the heart) were subsequently removed and minced finely. Then incubated with 2 mg/ml collagenase Type I (Gibco Laboratories), 5 mg/ml Dispase II (neutral protease, Grade II) (Roche) in DMEM (Sigma-Aldrich) in a 50-ml tube for 30 min in a 37°C water bath. Every 5-8 min during this incubation, the tube was gently agitated for a few seconds. After the 30-min incubation, the resulting tissue/cell suspension was filtered through a 40-µm strainer. The filter was washed with 5 ml of 1× PBS. The filtered cell suspension (∼35 ml) was centrifuged for 15 min at 1000 rpm. The cell pellet was washed once with complete DMEM, resuspended in warm DMEM supplemented with 20% FBS, 1% Antibiotic Antimycotic Solution (Corning) and 1 ng/ml bFGF (Roche), and plated into a gelatin-coated T-75 tissue culture flask. The following day, the cells from each lung were removed by trypsin and pooled together into one suspension for the sorting. The lung cell suspension was then subjected to magnetic beads sorting using anti-CD31 antibody. The sorted cells were resuspended in culture media described above and used for experiments. For MECs isolation from the brains, meninges from 14 days old mice were carefully removed from the forebrain and gray matter was minced and then digested with 2 mg/ml collagenase Type I (Gibco Laboratories), 5 mg/ml Dispase II (neutral protease, Grade II) (Roche) in DMEM (Sigma-Aldrich) containing 50 mg/ml gentamicin and 2 mM glutamine in 37°C water bath for 2 hours. The cell pellet was separated by centrifugation in 20% BSA-DMEM (1,000 × g, 20 minutes). The microvessels obtained in the pellet were further digested with 2mg/ml collagenase-dispase (Roche) in DMEM for 1.5 hours at 37°C, pelleted, washed with DMEM, and plated in DMEM supplemented with 20% FBS and 1 ng/ml bFGF (Roche). Freshly isolated primary MECs were used for all experiments without any further passages. We saw no difference in results between MECs isolated from lungs and brains.
MECs isolated from WT or Flk1 fl/fl ; iCDH5-ER T2 Cre (VEGFR2 fl/fl /iCDH5-ER T2 Cre) mice were treated with 5 µM of 4 hydroxytamoxifen (Sigma) dissolved in ethanol for two days at 37 0 C followed by incubation for additional two days without 4-hydroxytamoxifen. Deletion of VEGFR2 was confirmed by western blot using VEGFR2 antibody. Freshly isolated primary MECs were used for all experiments without any further passages.
Plasmids and transfection:
Mammalian expression plasmids for epsin 1 and VEGFR2 were described previously 12, 13 . Mutagenesis was performed using Quick Change II Site-Directed Mutagenesis Kit (Agilent Technologies; 200524). Mutagenesis primers and/or expression plasmids are available upon request. HEK 293T cells were transfected with indicated plasmids pull down mono-ubiquitin or poly-ubiquitin by his-tagged VEGFR2, Ni-NTA beads were incubated with equal amounts of VEGFR2 for half an hour at 4 0 C, then mixed with a predetermined amount of mono-ubiquitin or poly-ubiquitin (mono-ubiquitin is around 80 fold higher than poly-ubiquitin). The mixtures were further incubated at 4 0 C with rotation overnight. After centrifugation, the supernatant were removed. The beads were washed three times with RIPA buffer, then denatured in 2X Laemmli buffer and processed for Western blotting.
His-tagged di-ubiquitin pull-down of VEGFR2: Di-ubiquitin construct was kindly provided by Dr. Hao Wu, Department of Cellular and Molecular Medicine at Boston Children's Hospital. The overexpression and purification of di-ubiquitin were described previously 17 . The purified diubiquitin was first incubated with Ni-NTA beads, and then equal volume of beads was added to each cell lysate sample (wild type or mutant VEGFR2 expressing HEK293T cells) of equal total protein. The mixtures were incubated at 4 0 C with rotation overnight. After centrifugation, the supernatant were removed. The beads were washed three times with RIPA buffer, denatured in 2X Laemmli buffer, and processed for Western blotting.
Immunofluorescence staining of VEGFR2: HUVECs were transfected initially with VEGFR2-targeted siRNA, and then with wild type or mutant VEGFR2 constructs at 48 hr as described above. Twenty-four hours later, cells were serum starved overnight and incubated with 200 ng/ml of VEGF-A for 0 or 10 min at 37 °C. Cells were fixed with 4% formaldehyde in PBS, permeabilized, incubated with primary rabbit anti-VEGFR2 and goat polyclonal EEA 1 antibodies overnight, then incubation with respective donkey anti-rabbit ALEXA 488 and donkey anti goat ALEXA 594 conjugated secondary antibody for visualization. Cells were then thoroughly washed, cover slips mounted, and immunofluorescence images obtained using an Olympus IX81 Spinning Disc Confocal Microscope with an Olympus plan Apo Chromat 60x objective and Hamamatsu Orca-R2 Monochrome Digital Camera C1D600.
Biotinylation assay of cell surface VEGFR2 and Transferrin Receptor: Surface VEGFR2 and Transferrin Receptor levels were determined using a previously described surface biotinylation assay 1 . Briefly, HUVECs were transfected initially with VEGFR2-targeted siRNA, and then with wild type or mutant VEGFR2 constructs at 48 hr as described above. Twenty-four hours later, cells were serum starved overnight and incubated with 50 ng/ml of VEGF-A for 0 or 10 min at 37 °C to allow internalization of cell surface VEGFR2. At the end point, cells were placed on a rocking incubator at 4 °C with 1 mM EZ-Link Sulfo-NHS-LC-Biotin for 30 min, washed with 50 mM glycine to quench the biotinylation reaction, and lysed with RIPA buffer. Cleared lysates were processed for streptavidin bead pull down. Cell surface biotinylated VEGFR2 and Transferrin Receptor were visualized and quantified by Western blotting as described above.
In vitro EdU staining: MECs were grown on 0.2% gelatin-coated coverslips until they reached 50% confluence. Cells were incubated with UIM or UIM E3,4,5A peptides at 12.5 µM for 16 hrs, then serum starved for 4-6 hrs in DMEM. Subsequently, EdU was added to culture medium at 10 µM and cultured for an additional 16 hrs 18 . After labeling, cells were washed with PBS, fixed in 4% paraformaldehyde and permeabilized in 0.1% Triton X-100. EdU incorporation was detected by incubating fixed cells with 100 µM fluorescent azide diluted in 100 mM Tris, 0.5 mM CuSO 4 and 50 mM ascorbic acid. Cells were counterstained with 0.2 µg/mL DAPI then processed for imaging as described above.
In vitro angiogenesis assays: (1) Monolayer endothelial cell scratch "wound" assay:
Monolayer endothelial cell scratch "wound" assays were performed as described 2, 12 . Briefly, endothelial cells were cultured as described above with either UIM or UIM E3,4,5A peptide (12.5 µM) for 16 hrs. Cells were subsequently starved in DMEM for 8 hrs, then subjected to "wound injury" with a plastic pipette tip. Cells were treated with fresh medium supplemented with or without 50 ng/mL VEGF-A and either UIM or UIM E3,4,5A peptide (12.5 µM), and further cultured for 12 hrs. Quantification of wound distance at 12 hrs was performed using NIH Image J software. (2) Endothelial cell network formation: Endothelial cell network formation in Matrigel was performed as described 2, 12 . First, 0.3 mL of Matrigel was added to each well of a 24-well plate and incubated at 37°C for 1 hr. Endothelial cells were treated with UIM or UIM E3,4,5A peptide (12.5 µM) for 16 hrs, then starved as described and plated on Matrigel (4 x 10 4 cells per well). After 30 min, fresh medium supplemented with or without 50 ng/mL VEGF-A and either UIM or UIM E3,4,5A peptide (12.5 µM) was added and cells were incubated for an additional 16 hrs. Quantification of network formation at 16 hrs was performed using NIH ImageJ software.
Retina angiogenesis: C57BL/6J WT and EC-iDKO mice were administered UIM or UIM E3,4,5A peptide on postnatal day 2 (P2), P3, P4 and P5 via intraperitoneal injection (20 µg/g body weight). Pups were euthanized at P6, then the retinas were harvested from the dissected eyeball and processed for immunofluorescence whole-mount staining using biotinylated isolectin B4. Briefly, retinas were fixed in 4% paraformaldehyde for 1 hour then blocked in phosphate buffered saline (PBS) solution containing 5% donkey serum and 0.3% Triton X-100 for 1 hr and incubated at 4 °C for 16 hrs with biotinylated isolectin B4 diluted in blocking buffer (20 µg/mL). Retinas were subsequently washed with PBS and incubated for 1 hr at room temperature with fluorescently labeled streptavidin (Alexa Fluor) (Invitrogen). Samples were washed; retinas were mounted onto Superfrost/Plus microscope slides (Fisher Scientific). Flatmounted retinas were imaged at 5X magnification with AxioObserver.Z1 microscope (Zeiss) with a digital camera (AxioCam MRm; Zeiss). Individual images were merged to create one entire retinal image using the automated merge function (mosaiX; Zeiss) in the software (AxioVision 4.6.3.0; Zeiss). Vascular area was quantified using NIH Image J software. Quantification was determined by calculating isolectin B4-positive stained retinal area relative to total retinal area examined. Data is presented as relative vascular area.
In vivo Matrigel angiogenesis assay: Matrigel plug assay was performed as described previously 2, 19 . Briefly, twelve-week-old C57BL/6J WT mice were subcutaneously injected with 400 µL of unpolymerized growth factor-reduced phenol-free Matrigel supplemented with either PBS or VEGF-A (50 ng/mL) and specified peptides (100 µg/mL) while under anesthesia. Mice were euthanized after 7 days and the plugs removed. Plugs were photographed, formalin-fixed, cryopreserved and processed for immunostaining with anti-CD31 antibody as described previously.
In vivo wound healing angiogenesis assay: In vivo Wound Healing Assay was performed as described previously 2 . Under anesthesia, mice were wounded using a 4-mm-diameter fullthickness dorsal skin punch biopsy. Wounds were then photographed daily for 7 days after injury, and wound area was measured using NIH ImageJ software. On Day 7, the wounds were biopsied to include the margin of normal surrounding skin, fixed in cold 4% paraformaldehyde overnight and cryopreserved in Tissue-Tek OCT (Sakura). Cryosections were processed for immunofluorescence staining using anti-CD31 antibodies as described previously.
Animal study approval: All animal studies were performed in compliance with institutional guidelines and were approved by Institutional Animal Care and Use Committee (IACUC), Oklahoma Medical Research Foundation, Oklahoma City, OK and Boston Children's Hospital, Boston, MA.
Statistical analysis:
Data was shown as mean + S.E.M. Data was analyzed by the two-tailed student's t test or ANOVA, where appropriate. The Wilcoxon signed-rank test was used to compare data that did not satisfy the student's t test or ANOVA. A P value of less than 0.05 was considered significant.
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